HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This review highlights how the blockade of the co-stimulatory HVEM/LIGHT interaction or agonist signaling through the inhibitory BTLA and CD160 receptors could contribute to the control of deleterious immune responses. Immunosuppression is currently the treatment of choice to attenuate the chronic deterioration of tissue function as a result of the effector mechanisms of the immunological response in transplant rejection and autoimmune diseases. However, global immunosuppression greatly increases the risk of acquiring life-threatening infections and is associated with organ toxicity when used long-term. Thus, alternative approaches that inhibit only the unwanted immune responses and preserve general immunity are highly desirable. The receptor/ligand pairs involved in the cross-talk between DC and T cells have been the focus of intense and exciting research during the last decade. The HVEM/LIGHT/BTLA/CD160 costimulatory/coinhibitory pathway has emerged as a potential target for the development of immune therapeutic interventions. Herein, we will summarize and discuss how blockade of the costimulatory HVEM/LIGHT interaction or agonist signaling through the inhibitory BTLA and CD160 receptors could contribute to the control of deleterious immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“Inhibitory Ig SF members include CTLA-4, PD-1, BTLA, and the recently discovered coinhibitory molecule CD160 (also termed BY55) [11–15].”
BackgroundPlasticity of CD4+ T Cell Lineage Differentiation
Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 2×
“BTLA BTLA KO Spontaneous autoimmune hepatitis Increased susceptibility [63] BTLA KO EAE Increased susceptibility [14] BTLA KO Heart allograft class 1 MHC-mismatched 3 BTLA KO Decreased survival [69]”
Background
Cited by
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
M2b macrophage polarization and its roles in diseases
Wang, L.-X., Zhang, S.-X., Wu, H.-J., Rong, X.-L., & Guo, J. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru1018-378rr · Cited by 884
Deciphering the transcriptional network of the dendritic cell lineage
the Immunological Genome Consortium, Miller, J. C., Brown, B. D., Shay, T., Gautier, E. L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2370 · Cited by 781
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Buhl, T., Sulk, M., Nowak, P., Buddenkotte, J., McDonald, I., Aubert, J., Carlavan, I., Déret, S., Reiniche, P., Rivier, M., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.141 · Cited by 278
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.032 · Cited by 257
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Shui, J.-W., Steinberg, M. W., & Kronenberg, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910528 · Cited by 109
BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
Yu, X., Zheng, Y., Mao, R., Su, Z., & Zhang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00617 · Cited by 83
“Binding of HVEM to LIGHT or LIGHT-α exerts a positive stimulatory effect, stimulating lymphocyte proliferation, activation, and inducing inflammatory reactions; thus, providing a second stimulatory signal for T cell activation (4, 39).”
Background
Metadata
- Authors
- del Rio, M. L., Lucas, C. L., Buhler, L., Rayat, G., & Rodriguez-Barbosa, J. I.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-09
- Volume
- 87
- Issue
- 2
- Pages
- 223-235
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2026939258
- Cited by
- 157
- References
- 5
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.